Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress.

TET proteins, by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), are hypothesized, but not directly shown, to protect promoter CpG islands (CGIs) against abnormal DNA methylation (DNAm) in cancer. We define such a protective role linked to DNA damage from oxidative stress (OS) known to induce this abnormality. TET2 removes aberrant DNAm during OS through interacting with DNA methyltransferases (DNMTs) in a "Yin-Yang" complex targeted to chromatin and enhanced by p300 mediated TET2 acetylation. Abnormal gains of DNAm and 5hmC occur simultaneously in OS, and knocking down TET2 dynamically alters this balance by enhancing 5mC and reducing 5hmC. TET2 reduction results in hypermethylation of promoter CGIs and enhancers in loci largely overlapping with those induced by OS. Thus, TET2 indeed may protect against abnormal, cancer DNAm in a manner linked to DNA damage.

[1]  S. Baylin,et al.  Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island , 2008, PLoS genetics.

[2]  K. Helin,et al.  DNA methylation: TET proteins—guardians of CpG islands? , 2012, EMBO reports.

[3]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[4]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[5]  William A. Pastor,et al.  TETonic shift: biological roles of TET proteins in DNA demethylation and transcription , 2013, Nature Reviews Molecular Cell Biology.

[6]  S. Gygi,et al.  Acetylation-Dependent Regulation of Skp2 Function , 2012, Cell.

[7]  A. Rao,et al.  Acute loss of TET function results in aggressive myeloid cancer in mice , 2015, Nature Communications.

[8]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[9]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[10]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[11]  Yi Zhang,et al.  TET enzymes, TDG and the dynamics of DNA demethylation , 2013, Nature.

[12]  C. Iacobuzio-Donahue,et al.  Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers , 2011, Oncotarget.

[13]  L. Aravind,et al.  Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX , 2013, Nature.

[14]  G. Hon,et al.  Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.

[15]  R. Levine,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[16]  Xing Zhang,et al.  Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA , 2013, Nature.

[17]  S. Balasubramanian,et al.  oxBS-450K: A method for analysing hydroxymethylation using 450K BeadChips , 2015, Methods.

[18]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[19]  Martin J. Aryee,et al.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer , 2011, Genome research.

[20]  Hao Wu,et al.  Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions , 2014, Cell.

[21]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[22]  Sebastian A. Wagner,et al.  Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. , 2013, Cell reports.

[23]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[24]  P. Jin,et al.  Genome-wide Profiling of 5-Formylcytosine Reveals Its Roles in Epigenetic Priming , 2013, Cell.

[25]  S. Baylin,et al.  Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.

[26]  O. Bernard,et al.  TET proteins and the control of cytosine demethylation in cancer , 2015, Genome Medicine.

[27]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[28]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[29]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[30]  Lee E. Edsall,et al.  5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. , 2014, Molecular cell.

[31]  T. Horii,et al.  5-Hydroxymethylcytosine Marks Sites of DNA Damage and Promotes Genome Stability. , 2016, Cell reports.

[32]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[33]  E. Kremmer,et al.  Phosphorylation of TET Proteins Is Regulated via O-GlcNAcylation by the O-Linked N-Acetylglucosamine Transferase (OGT)* , 2015, The Journal of Biological Chemistry.

[34]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[35]  S. Baylin,et al.  Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. , 2016, Journal of molecular cell biology.

[36]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[37]  L. Coussens,et al.  Inflammation and Cancer , 2016 .

[38]  Xiaodong Cheng,et al.  Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation , 2012, Nucleic acids research.

[39]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[40]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[41]  G. Schackert,et al.  5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.

[42]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[43]  B. Porse,et al.  Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis , 2015, Genes & development.

[44]  Xian Chen,et al.  CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. , 2015, Molecular cell.

[45]  A. Georgakilas,et al.  Oxidative stress, DNA methylation and carcinogenesis. , 2008, Cancer letters.

[46]  F. Ciardiello,et al.  Chronic inflammation and oxidative stress in human carcinogenesis , 2007, International journal of cancer.

[47]  Yi Zhang,et al.  Regulation of TET protein stability by calpains. , 2014, Cell reports.

[48]  Ze Li,et al.  Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation , 2013, Cell.

[49]  Yi Zhang,et al.  Role of Tet proteins in enhancer activity and telomere elongation , 2014, Genes & development.

[50]  P. Pandolfi,et al.  The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. , 2013, Cell stem cell.